Know Labs Inc (KNW)

[tim00mike]

Dexcom CEO touts unprecedented performance of G7 in clinical trial, awaits FDA decision

https://www.drugdeliverybusiness.com/dexcom-ceo-touts-unprecedented-performance-of-g7-in-clinical-trial-awaits-fda-decision/

Exciting new data for the next-generation Dexcom (NSDQ:DXCM) G7 continuous glucose monitor (CGM) surprised even the company’s leadership.

“The performance of this product is something I never really thought I would see in nearly 30 years in this business,” Sayer said during his J.P. Morgan presentation.

G7 features a 60% size reduction from the G6, a 30-minute warmup period, more information in one place with personalized insights, extended-wear design and more.

Data presented by Sayer and Dexcom highlighted strong performance to accompany the new and improved features of the next-generation technology. G7 outperformed ICGM standards established by the FDA across the board with its time-in-range performance, including overall time-in-range (measured by percentage within 20%) with a tally of 93.3% compared to the FDA standard of 87%.

Mean absolute relative difference (MARD) for G7 registered at 8.1% in pediatric patients and 8.2% in adult patients, highlighting consistency to accompany performance.